Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + prednisolone + procarbazine + vincristine
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a multi-agent chemotherapy combination consisting of four drugs: - Cyclophosphamide (an alkylating agent) - Vincristine (a vinca alkaloid) - Procarbazine (an alkylating agent) - Prednisolone (a synthetic glucocorticoid corticosteroid) The regimen is used primarily in the treatment of Hodgkin lymphoma and non-Hodgkin lymphoma. Each component acts via a different mechanism to inhibit cancer cell growth and proliferation. Cyclophosphamide and procarbazine are cytotoxic agents that damage DNA; vincristine disrupts microtubule formation during cell division; prednisolone exerts anti-inflammatory and immunosuppressive effects as well as direct cytotoxicity to certain lymphoid cells[1][3][6].
- Other names
- cyclophosphamide, vincristine, procarbazine, prednisolone combinationCOPP regimenC-MOPP regimen
02
Targets
GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cyclophosphamide + prednisolone + procarbazine + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + prednisolone + procarbazine + vincristine.